Vilon: Two Amino Acids, and the Question of How Small a Signal Can Be

What Is Vilon?

Vilon is a dipeptide — lysine joined to glutamic acid, written Lys-Glu or simply KE. Two amino acids. It is among the shortest molecules in the entire bioregulator family, and one of the shortest things that can meaningfully be called a peptide at all.

It emerged from the same thymic research that produced the extract Thymalin. Where Thymalin is a mixture of peptides pulled from thymus tissue, Vilon is a single defined molecule that can be synthesised precisely and verified analytically — the second generation of the same idea.

How small is small, in plain language: if a protein is a novel and a typical research peptide is a sentence, Vilon is a two-letter word. The obvious objection is that a two-letter word cannot carry much meaning — and that is exactly the objection the bioregulator programme set out to answer. Their argument is that in biology, as in language, the shortest words are often the most load-bearing: no, go, on. Whether two amino acids really can carry a specific instruction is the open question this compound sits on top of.

What the Research Examines

Published work on Vilon centres on immune function, particularly in ageing models. The institute’s studies report effects on thymocyte differentiation — the maturation process that turns immature immune cells into functioning T-cells — and on immune response measures in aged animals.

Some of the more interesting mechanistic work examines whether these very short peptides can enter the cell nucleus at all. Studies using fluorescence-labelled peptides have reported nuclear penetration in cultured human cells, which is the sort of finding the whole proposed mechanism depends on. It is worth noting that this line of work also comes largely from the same research group.

Vilon has also appeared in studies examining chromatin structure — how tightly DNA is packed — on the reasoning that a peptide influencing gene expression would need to affect DNA accessibility rather than the genetic code itself.

The Evidence, Honestly

Vilon has a considerably thinner published record than Epitalon or Thymalin, and it would be misleading to present it otherwise.

The available studies are largely preclinical — cell culture and animal models — and the great majority originate from the St. Petersburg institute that developed the compound. Independent replication outside that programme is minimal. There is no regulatory approval in any jurisdiction, including Russia, where several other family members do hold approvals.

That does not make it uninteresting. A defined two-amino-acid sequence is an unusually clean thing to study, and if the bioregulator mechanism holds anywhere it should be testable here. But the honest position is that this is an early-stage research compound with a small evidence base, not an established one.

Frequently Asked Questions

Published References

1. Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
2. Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed
3. Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
4. Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed